Dexketoprofen
Brand names: Keral, Sympal
Dexketoprofen is a non-steroidal anti-inflammatory drug (the active enantiomer of ketoprofen) used for the short-term relief of mild to moderate acute pain.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It non-selectively inhibits cyclo-oxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and thereby producing analgesic, anti-inflammatory and antipyretic effects.
Prescribing in practice
- Like other NSAIDs it carries risks of gastrointestinal ulceration and bleeding, cardiovascular and renal adverse effects, so it should be used at the lowest effective dose for the shortest duration.
- Contraindicated in active or previous peptic ulceration/GI bleeding, severe heart failure, significant renal impairment and in late pregnancy.
- Use caution with other NSAIDs, anticoagulants, antiplatelets, and drugs affecting renal function, and consider gastroprotection in at-risk patients per current prescribing references.
Monitoring
Assess renal function, blood pressure and for gastrointestinal symptoms, particularly in older or at-risk patients and with longer use.
Counselling the patient
- Take with or after food and use it only for short-term pain relief.
- Stop and seek advice if you develop indigestion, black stools or signs of gastrointestinal bleeding.
- Avoid taking other anti-inflammatory painkillers (including over-the-counter ones) at the same time.
Evidence & guidelines
NSAID gastrointestinal, cardiovascular and renal risks are well established and reflected in MHRA advice and the SPC.
Reference: NICE NG100; NICE CKS NSAIDs; MHRA; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022